EGFR mutant (EGFRm) metastatic non-small cell lung cancer (NSCLC) is generally sensitive to tyrosine kinase inhibitors (TKIs), considered the standard first line of treatment (11, 12) . This evidence concerns the gene EGFR and non-small cell lung carcinoma.